DNA methylation affects metastasis of renal cancer and is associated with TGF-β/RUNX3 inhibition

Zheng, Jianbo; Mei, Yanhui; Xiang, Ping; Zhai, Guangsheng; Zhao, Ning; Xu, Chuanbing; Liu, Min; Pan, Zhengsheng; Tang, Kai Fu; Jia, Dongsheng

doi:10.1186/s12935-018-0554-7

Cited by 24 publications

(17 citation statements)

References 28 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…JAK-STAT signaling pathway induces interferon-γ (IFN- γ) to express TGF-β signaling pathways inhibitor, Smad7 (80). JAK-STAT signaling pathway indirectly affect the expression of RUNX3 as this gene is closely linked to TGF- β signaling pathways (81–83). By indirect binding of STAT3 and bone morphogenetic proteins (BMP)-specific Smads, BMP pathways interact with Leukemia inhibitory factor (LIF) induce differentiation of astrocytes from neuroepithelial cells (84).…”

Section: Crosstalk Between Stats With Other Transcription Factors In mentioning

confidence: 99%

Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication

et al. 2019

View full text Add to dashboard Cite

Signal Transducer and Activator of Transcription (STAT) pathway is connected upstream with Janus kinases (JAK) family protein and capable of integrating inputs from different signaling pathways. Each family member plays unique functions in signal transduction and crucial in mediating cellular responses to different kind of cytokines. STAT family members notably STAT3 and STAT5 have been involved in cancer progression whereas STAT1 plays opposite role by suppressing tumor growth. Persistent STAT3/5 activation is known to promote chronic inflammation, which increases susceptibility of healthy cells to carcinogenesis. Here, we review the role of STATs in cancers and inflammation while discussing current therapeutic implications in different cancers and test models, especially the delivery of STAT3/5 targeting siRNA using nanoparticulate delivery system.

show abstract

Section: Crosstalk Between Stats With Other Transcription Factors In mentioning

confidence: 99%

Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Apart from associating imaging features with genetic mutations, they can also be associated with biomarkers such as DNA methylation, which is known to play a key role in cancer development and has potential prognostic and diagnostic value [106][107][108][109]. DNA methylation in tumor suppressor genes including RUNX3 negatively impacts survival in some cancers [110][111][112][113][114][115]. An exploratory study by Cen et al [116] divided RCC patients into high RUNX3 methylation and low RUNX3 methylation groups.…”

Section: Kidneymentioning

confidence: 99%

Combining molecular and imaging metrics in cancer: radiogenomics

et al. 2020

View full text Add to dashboard Cite

Background: Radiogenomics is the extension of radiomics through the combination of genetic and radiomic data. Because genetic testing remains expensive, invasive, and time-consuming, and thus unavailable for all patients, radiogenomics may play an important role in providing accurate imaging surrogates which are correlated with genetic expression, thereby serving as a substitute for genetic testing. Main body: In this article, we define the meaning of radiogenomics and the difference between radiomics and radiogenomics. We provide an up-to-date review of the radiomics and radiogenomics literature in oncology, focusing on breast, brain, gynecological, liver, kidney, prostate and lung malignancies. We also discuss the current challenges to radiogenomics analysis. Conclusion: Radiomics and radiogenomics are promising to increase precision in diagnosis, assessment of prognosis, and prediction of treatment response, providing valuable information for patient care throughout the course of the disease, given that this information is easily obtainable with imaging. Larger prospective studies and standardization will be needed to define relevant imaging biomarkers before they can be implemented into the clinical workflow.

show abstract

“…These results were recapitulated by a metastatic and primary renal cancer mice xenograft model. Pretreatment of cancer cells with 5-aza-2'-deoxycytidine (DNA methylation inhibitor) before inoculation in mice led to increased TGF-β1 expression, tumor size reduction, and an extended survival time of animals [138].…”

Section: Renal Cancermentioning

confidence: 99%

TGF-β and microRNA Interplay in Genitourinary Cancers

Bogusławska¹,

Kryst

Poletajew

et al. 2019

Cells

View full text Add to dashboard Cite

Genitourinary cancers (GCs) include a large group of different types of tumors localizing to the kidney, bladder, prostate, testis, and penis. Despite highly divergent molecular patterns, most GCs share commonly disturbed signaling pathways that involve the activity of TGF-β (transforming growth factor beta). TGF-β is a pleiotropic cytokine that regulates key cancer-related molecular and cellular processes, including proliferation, migration, invasion, apoptosis, and chemoresistance. The understanding of the mechanisms of TGF-β actions in cancer is hindered by the “TGF-β paradox” in which early stages of cancerogenic process are suppressed by TGF-β while advanced stages are stimulated by its activity. A growing body of evidence suggests that these paradoxical TGF-β actions could result from the interplay with microRNAs: Short, non-coding RNAs that regulate gene expression by binding to target transcripts and inducing mRNA degradation or inhibition of translation. Here, we discuss the current knowledge of TGF-β signaling in GCs. Importantly, TGF-β signaling and microRNA-mediated regulation of gene expression often act in complicated feedback circuits that involve other crucial regulators of cancer progression (e.g., androgen receptor). Furthermore, recently published in vitro and in vivo studies clearly indicate that the interplay between microRNAs and the TGF-β signaling pathway offers new potential treatment options for GC patients.

show abstract

DNA methylation affects metastasis of renal cancer and is associated with TGF-β/RUNX3 inhibition

Cited by 24 publications

References 28 publications

Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication

Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication

Combining molecular and imaging metrics in cancer: radiogenomics

TGF-β and microRNA Interplay in Genitourinary Cancers

Contact Info

Product

Resources

About